visualizations
Tullius, Brian Patrick, MD
Overview
overview
- Brian Tullius, MD, is a board-certified pediatrician. Dr. Tullius received his medical degree at the University of Nebraska College of Medicine in Omaha Nebraska after completing a Master of Arts degree in Philosophy and a Bachelor of Arts in Philosophy and Biology from Franciscan University of Steubenville in Steubenville, Ohio. He has extensive training in pediatrics, completing pediatric internship at the Naval Medical Center in San Diego and pediatric residency at the University of California-Davis Medical Center in Sacramento. Dr. Tullius completed flight surgeon training at the Naval Aerospace Medical Institute in Pensacola, FL, and his pediatric hematology/oncology as well as his cellular therapy fellowships at Nationwide Children’s Hospital in Columbus, Ohio. He served in the United States Navy achieving the rank of Lieutenant Commander and receiving numerous awards and commendations for his outstanding service. Dr. Tullius has a U.S. Patent on a cellular therapy for treating microbial infections, and a patent pending for an innovative website he helped design to improve access to and awareness of clinical trials. An accomplished medical practitioner, Dr. Tullius specializes in cellular therapies, cancer immunotherapy, innate immunity and stem cell transplantation.
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2023Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 11.Full Text via DOI: 10.1136/jitc-2023-007502 PMID: 38081778
-
2023Natural killer cells for antiviral therapy. SCIENCE TRANSLATIONAL MEDICINE. 15.PMID: 36599006
-
2022CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy. FRONTIERS IN ONCOLOGY.Full Text via DOI: 10.3389/fonc.2022.834002 PMID: 35449580
-
2021Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. STEM CELL RESEARCH & THERAPY.Full Text via DOI: 10.1186/s13287-021-02277-x PMID: 33766099
-
2021COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients. JOURNAL OF INFECTION. 329-338.Full Text via DOI: 10.1016/j.jinf.2021.01.022 PMID: 33549624
-
2020Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity. SEMINARS IN HEMATOLOGY. 57:201-212.Full Text via DOI: 10.1053/j.seminhematol.2020.11.006 PMID: 33256913
-
2020Natural Killer Cell Immunotherapy for Osteosarcoma. CURRENT ADVANCES IN OSTEOSARCOMA: CLINICAL PERSPECTIVES: PAST, PRESENT AND FUTURE, 2ND EDITION. 1257:141-154.Full Text via DOI: 10.1007/978-3-030-43032-0_12 PMID: 32483737
-
2020Therapeutic modulation of the CD47-SIRPalpha axis in the pediatric tumor microenvironment: working up an appetite.. Cancer drug resistance (Alhambra, Calif.). 550-562.Full Text via DOI: 10.20517/cdr.2020.12 PMID: 35582455
-
2019Novel heterozygous mutation in the PTEN gene associated with ovarian germ cell tumor complicated by growing teratoma syndrome and overgrowth in a two-year-old female. PEDIATRIC BLOOD & CANCER. 66.Full Text via DOI: 10.1002/pbc.27788 PMID: 31038288
-
2018Hospital-to-Home Interventions, Use, and Satisfaction: A Meta-analysis. PEDIATRICS.Full Text via DOI: 10.1542/peds.2018-0442 PMID: 30352792
-
2018The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 16:175-180.Full Text via DOI: 10.1111/jth.13895 PMID: 29178421
Background
Full Name
- Brian Patrick Tullius, MD
Education
- University of Nebraska College of Medicine, Omaha, NE
Residency
- Pediatrics at UC Davis School of Medicine
Fellowship
- Bone Marrow at Nationwide Children's Hospital
Contact
primary email
- Research.Institute@AdventHealth.com